Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein

British Journal of Pharmacology

Volumn 148, Issue 6, 2006, Pages 786-794

  Lee, Anna M ^a   Miksys, Sharon ^a   Tyndale, Rachel F ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Brain protein induction; CYP2B6; In vivo kinetics; Monkey; Nicotine; Phenobarbital

Indexed keywords

BRAIN ENZYME; CYTOCHROME P450 2B6; LIVER ENZYME; NICOTINE; PHENOBARBITAL; SACCHARIN;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN STEM; CAUDATE NUCLEUS; CERCOPITHECIDAE; CEREBELLUM; CONTROLLED STUDY; DRUG METABOLISM; FRONTAL CORTEX; HIPPOCAMPUS; IN VIVO STUDY; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PUTAMEN; PYRAMIDAL NERVE CELL; SUPPLEMENTATION; THALAMUS;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BRAIN; CERCOPITHECUS AETHIOPS; ENZYME INDUCTION; IMMUNOHISTOCHEMISTRY; LIVER; MALE; NICOTINE; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOBARBITAL;

EID: 33746060489     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706787     Document Type: Article

References (48)

1. ANANDATHEERTHAVARADA, H.K., BOYD, M.R. & RAVINDRANATH, V. (1992). Characterization of a phenobarbital-inducible cytochrome P-450, NADPH-cytochrome P-450 reductase and reconstituted cytochrome P-450 mono-oxygenase system from rat brain. Evidence for constitutive presence in rat and human brain. Biochem. J., 288, 483-488.
2. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem., 72, 248-254.
3. BULLOCK, P., PEARCE, R., DRAPER, A., PODVAL, J., BRACKEN, W., VELTMAN, J., THOMAS, P. & PARKINSON, A. (1995). Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab. Dispos., 23, 736-748.
4. CHUNG, W.G., ROH, H.K., KIM, H.M. & CHA, Y.N. (1998). Involvement of CYP3A1, 2B1, and 2E1 in C-8 hydroxylation and CYP 1A2 and flavin-containing monooxygenase in N-demethylation of caffeine; identified by using inducer treated rat liver microsomes that are characterized with testosterone metabolic patterns. Chem. Biol. Interact., 113, 1-14.
5. DALEN, P., DAHL, M.L., EICHELBAUM, M., BERTILSSON, L. & WILKINSON, G.R. (1999). Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics, 9, 697-706.
6. DHAWAN, A., PARMAR, D., DAYAL, M. & SETH, P.K. (1999). Cytochrome P450 (P450) isoenzyme specific dealkylation of alkoxyresorufins in rat brain microsomes. Mol. Cell Biochem., 200, 169-176.
7. DICKE, K.E., SKRLIN, S.M. & MURPHY, S.E. (2005). Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome p450 2b6. Drug Metab. Dispos., 33, 1760-1764.
8. DONATO, M.T., VIITALA, P., RODRIGUEZ-ANTONA, C., LINDFORS, A., CASTELL, J.V., RAUNIO, H., GOMEZ-LECHON, M.J. & PELKONEN, O. (2000). CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab. Dispos., 28, 1321-1326.
9. FAUCETTE, S.R., HAWKE, R.L., LECLUYSE, E.L., SHORD, S.S., YAN, B., LAETHEM, R.M. & LINDLEY, C.M. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos., 28, 1222-1230.
10. FOTH, H., WALTHER, U.I. & KAHL, G.F. (1990). Increased hepatic nicotine elimination after phenobarbital induction in the conscious rat. Toxicol. Appl. Pharmacol., 105, 382-392.
11. FRADETTE, C., YAMAGUCHI, N. & DU SOUICH, P. (2004). 5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide. Br. J. Pharmacol., 141, 407-414.
12. GERVOT, L., ROCHAT, B., GAUTIER, J.C., BOHNENSTENGEL, F., KROEMER, H., DE BERARDINIS, V., MARTIN, H., BEAUNE, P. & DE WAZIERS, I. (1999). Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics, 9, 295-306.
13. GOLDFARB, I., KORZEKWA, K., KRAUSZ, K.W., GONZALEZ, F. & GELBOIN, H.V. (1993). Cross-reactivity of thirteen monoclonal antibodies with ten vaccinia cDNA expressed rat, mouse and human cytochrome P450s. Biochem. Pharmacol., 46, 787-790.
14. GOODWIN, B., MOORE, L.B., STOLTZ, C.M., MCKEE, D.D. & KLIEWER, S.A. (2001). Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol., 60, 427-431.
15. HUANG, Z., ROY, P. & WAXMAN, D.J. (2000). Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol., 59, 961-972.
16. HUKKANEN, J., JACOB III, P. & BENOWITZ, N.L. (2005). Metabolism and disposition kinetics of nicotine. Pharmacol. Rev., 57, 79-115.
17. JACOB III, P., ULGEN, M. & GORROD, J.W. (1997). Metabolism of (-)-(S)-nicotine by guinea pig and rat brain: identification of cotinine. Eur. J. Drug Metab. Pharmacokinet., 22, 391-394.
18. JONES, C.R., GUENGERICH, F.P., RICE, J.M. & LUBET, R.A. (1992). Induction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates. Pharmacogenetics, 2, 160-172.
19. JUSHCHYSHYN, M.I., KENT, U.M. & HOLLENBERG, P.F. (2003). The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab. Dispos., 31, 46-52.
20. KRETH, K., KOVAR, K., SCHWAB, M. & ZANGER, U.M. (2000). Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs. Biochem. Pharmacol., 59, 1563-1571.
21. LAMBA, J.K., LAMBA, V., YASUDA, K., LIN, Y.S., ASSEM, M., THOMPSON, E., STROM, S. & SCHUETZ, E.G. (2004). Expression of CAR splice variants in human tissues and their functional consequences. J. Pharmacol. Exp. Ther., 311, 811-821.
22. LEE, A.M., MIKSYS, S., PALMOUR, R. & TYNDALE, R.F. (2006). CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology, 50, 441-450.
23. MARTIN, R.F. & BOWDEN, D.M. (2000). Primate Brain Maps: Structure of the macaque brain: A Laboratory Guide with Original Brain Sections. Amsterdam, Oxford: Elsevier (Printed atlas and electronic templates for data and schematics by Richard F. Martin and Douglas M. Bowden; software by John Wu, Mark F. Dubach and Joan E. Robertson).
24. MCMORROW, M.J. & FOXX, R.M. (1983). Nicotine's role in smoking: an analysis of nicotine regulation. Psychol. Bull., 93, 302-327.
25. MESSINA, E.S., TYNDALE, R.F. & SELLERS, E.M. (1997). A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther., 282, 1608-1614.
26. MIKSYS, S., HOFFMANN, E. & TYNDALE, R.F. (2000). Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem. Pharmacol., 59, 1501-1511.
27. MIKSYS, S., LERMAN, C., SHIELDS, P.G., MASH, D.C. & TYNDALE, R.F. (2003). Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology, 45, 122-132.
28. OHMORI, S., HORIE, T., GUENGERICH, F.P., KIUCHI, M. & KITADA, M. (1993). Purification and characterization of two forms of hepatic microsomal cytochrome P450 from untreated cynomolgus monkeys. Arch. Biochem. Biophys., 305, 405-413.
29. PARMAR, D., DHAWAN, A. & SETH, P.K. (1998). Evidence for O-dealkylation of 7-pentoxyresorufin by cytochrome P450 2B1/2B2 isoenzymes in brain. Mol. Cell Biochem., 189, 201-205.
30. PASCUSSI, J.M., GERBAL-CHALOIN, S., DROCOURT, L., MAUREL, P. & VILAREM, M.J. (2003). The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta., 1619, 243-253.
31. RAO, Y., HOFFMANN, E., ZIA, M., BODIN, L., ZEMAN, M., SELLERS, E.M. & TYNDALE, R.F. (2000). Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol., 58, 747-755.
32. ROTGER, M., COLOMBO, S., FURRER, H., BLEIBER, G., BUCLIN, T., LEE, B.L., KEISER, O., BIOLLAZ, J., DECOSTERD, L. & TELENTI, A. (2005). Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics, 15, 1-5.
33. SCHILTER, B., ANDERSEN, M.R., ACHARYA, C. & OMIECINSKI, C.J. (2000). Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers. J. Pharmacol. Exp. Ther., 294, 916-922.
34. SCHILTER, B. & OMIECINSKI, C.J. (1993). Regional distribution and expression modulation of cytochrome P-450 and epoxide hydrolase mRNAs in the rat brain. Mol. Pharmacol., 44, 990-996.
35. SCHOEDEL, K.A., SELLERS, E.M., PALMOUR, R. & TYNDALE, R.F. (2003). Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol. Pharmacol., 63, 96-104.
36. SELLERS, E.M., KAPLAN, H.L. & TYNDALE, R.F. (2000). Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther., 68, 35-43.
37. SELLERS, E.M., RAMAMOORTHY, Y., ZEMAN, M.V., DJORDJEVIC, M.V. & TYNDALE, R.F. (2003). The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob. Res., 5, 891-899.
38. SLOAN, T.P., LANCASTER, R., SHAH, R.R., IDLE, J.R. & SMITH, R.L. (1983). Genetically determined oxidation capacity and the disposition of debrisoquine. Br. J. Clin. Pharmacol., 15, 443-450.
39. SMITH, G.B., BEND, J.R., BEDARD, L.L., REID, K.R., PETSIKAS, D. & MASSEY, T.E. (2003). Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) in peripheral human lung microsomes. Drug Metab. Dispos., 31, 1134-1141.
40. SNIDER, R.S. & LEE, J.C. (1961). A sterotaxic atlas of the monkey brain (Macaca mulatta). Chicago, University Press.
41. SOARS, M.G., PETULLO, D.M., ECKSTEIN, J.A., KASPER, S.C. & WRIGHTON, S.A. (2004). An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab. Dispos., 32, 140-148.
42. STOLERMAN, I.P. & JARVIS, M.J. (1995). The scientific case that nicotine is addictive. Psychopharmacology (Berlin), 117, 2-10; discussion 14-20.
43. UPADHYA, S.C., CHINTA, S.J., PAI, H.V., BOYD, M.R. & RAVIN-DRANATH, V. (2002). Toxicological consequences of differential regulation of cytochrome p450 isoforms in rat brain regions by phenobarbital. Arch. Biochem. Biophys., 399, 56-65.
44. WANG, H. & NEGISHI, M. (2003). Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors. Curr. Drug Metab., 4, 515-525.
45. WARD, B.A., GORSKI, J.C., JONES, D.R., HALL, S.D., FLOCKHART, D.A. & DESTA, Z. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther., 306, 287-300.
46. XU, C., RAO, Y.S., XU, B., HOFFMANN, E., JONES, J., SELLERS, E.M. & TYNDALE, R.F. (2002). An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun., 290, 318-324.
47. YAMANAKA, H., NAKAJIMA, M., FUKAMI, T., SAKAI, H., NAKAMURA, A., KATOH, M., TAKAMIYA, M., AOKI, Y. & YOKOI, T. (2005). CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab. Dispos, 33, 1811-1818.
48. YAMAZAKI, H., INOUE, K., HASHIMOTO, M. & SHIMADA, T. (1999). Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol., 73, 65-70.